CLSP 5282 for Advanced Solid Tumors With KRas G12V Mutation
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This early-stage trial tests a new immunotherapy called CLSP 5282 designed for patients with advanced solid cancers that have a specific genetic change (KRas G12V mutation) and a matching immune marker (HLA-A*03:01). The treatment aims to help your immune system recognize and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Advanced or spread cancer (solid tumor) that has progressed despite standard treatment or has no standard treatment available
- Cancer must have the KRas G12V genetic mutation, confirmed by lab testing
- Must have the HLA-A*03:01 immune marker (determined by central blood test)
- Good overall health status and ability to function with minimal restrictions (ECOG 0–1)
- Adequate organ function (blood counts, kidney, and liver)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
This trial tests a combination of two experimental drugs (SY-5933 and CT-707) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective.
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
This trial tests a new drug (HS-10370) combined with other cancer treatments for people with advanced lung cancer that has a specific mutation called KRAS G12C. It is for those who have not yet received systemic therapy for their advanced disease.
This trial tests a personalized vaccine designed to target cancers with specific KRAS gene mutations. It may be an option for adults whose advanced solid tumor (like pancreatic or lung cancer) has not responded to standard treatments.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.